Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on February 14, 2014. The filing discloses the departure of Beatrice Cazala, who previously served as an executive officer, and details the terms of her separation agreement effective as of the filing date.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
| Item | Value |
|---|---|
| Gross Cash Severance Payment | Approximately $3 million |
| Lump Sum Settlement Payment | $1.5 million (paid in three installments) |
| Expense Reimbursement | $185,000 (attorneys' fees, moving, tax services) |
| Total Cash Consideration Disclosed | Approximately $4.685 million |
Material Changes
The primary material change is the termination of Ms. Cazala's employment letter agreement for her U.S. assignment and the subsequent termination of her reinstated French employment contract. Her separation is scheduled to be effective June 9, 2014. She will remain an active employee in the U.S. as Executive Vice President until that date.
Outlook, Risks, and Unusual Items
Compensatory Arrangements: Ms. Cazala remains eligible for her 2013 annual incentive award and the continued vesting of previously awarded unvested stock units. She is not eligible for 2014 annual or long-term incentive awards. Awards outstanding for less than one year will lapse.
Legal and Operational Risks: The agreement includes a general release of claims against the Company and its affiliates. Ms. Cazala has agreed to confidentiality, non-disparagement, and a six-month non-compete restriction following her separation date. She has also agreed to cooperate with any investigations or legal proceedings related to her employment.
Investor Verification Checklist
- Verify the total cost of the separation package, including the $3 million severance, $1.5 million settlement, and $185,000 in reimbursements.
- Confirm the impact on the company's compensation expense for the fiscal year ending 2014 due to the forfeiture of awards outstanding for less than one year.
- Review the specific terms of the non-compete and non-disparagement covenants to assess potential operational risks.
- Monitor the vesting schedule of Ms. Cazala's remaining stock units to determine future equity dilution or expense recognition.